Dr. Harry D. Harper, MD

Dr. Harper practices at Hackensack University Medical Center in Hackensack, New Jersey, part of Hackensack Meridian Health.

Dr. Harper's NPI, 1811958481, was assigned on March 31, 2006. Dr. Harper graduated from Baylor College of Medicine in 1977. Dr. Harper holds New Jersey license 25MA04174300.

Dr. Harper's primary practice is Hackensack University Medical Center, at 30 Prospect Ave, Hackensack, NJ 07601 in Bergen County. The practice phone is (551) 996-2000.

Dr. Harper's primary practice is Hackensack University Medical Center in Hackensack, New Jersey, part of Hackensack Meridian Health. Dr. Harper is also affiliated with St. Joseph's University Medical Center. The medical group on file is Regional Cancer Care Associates. Dmand AI also links Dr. Harper to 2 more group practices and clinics, 1 home health agency and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Harper practices, 5 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Harper's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Harper is licensed in New Jersey.

CMS data shows 38,087 Medicare services from Dr. Harper across 17 procedure codes in 2024, for 483 Medicare patients. Medicare paid $388,833 for them.

CMS counts 483 Medicare patients who saw Dr. Harper in 2024. The largest group is 65 to 74, with 191 patients. 75% of them have cancer, and 75% have high blood pressure. 13% are also on Medicaid. Their average risk score is 2.71, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Harper's median patient age at 71, with 57% women.

In 2024, Dr. Harper wrote 449 Medicare Part D claims for 106 patients. 67% of them were for generic drugs. CMS names the drug for 265 of them, across 12 drugs with 11 or more claims each, at $1,475,594 in total drug cost. In 2023, CMS named 217 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Harper for performance year 2024. Dr. Harper accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 4 papers to Dr. Harper, published from 2011 to 2017. 2017 was the busiest year, with 2. The most frequent topics are Lung Neoplasms. Dr. Harper's most frequent co-authors are Daniel S. Bradford, MD, Jeffrey M. Crane, MD and Stuart Leigh Goldberg, MD.

Dmand AI links Dr. Harper to 3 clinical trials. 1 is still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Cluster Headache and Headache. Eli Lilly and Company sponsors the most, 2. Open Payments lists research payments to Dr. Harper that name 2 trials.

CMS Open Payments shows 1,093 general payments to Dr. Harper from 60 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 75% of the total. Bristol-Myers Squibb Company paid the most, $212,447. It also lists 4 research payments totaling $6,004 from 2016 to 2018, naming 2 clinical trials.

Dr. Harper graduated from Baylor College of Medicine in 1977.